The pharmaceutical firm Novo Nordisk is pursuing a multi-pronged strategy to regain market share … More that it has lost to Eli Lilly in the lucrative obesity drug market. One of its weight loss products, Wegovy (semaglutide), is an injectable prescription medicine. It should be used with a weight loss plan and (increased) physical activity. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images)
Leave a Reply